文献速递心外重症与机械循环支持

经侧胸廓切开术植入左心室辅助装置:系统评价与Meta分析

Left ventricular assist device implantation via lateral thoracotomy: A systematic review and meta-analysis.
PubMed 文献 · J Heart Lung Transplant · 2022-07-11

该系统评价与Meta分析纳入25项观察性研究共3072例患者,比较经侧胸廓切开术(LT)与正中胸骨切开术植入连续流左心室辅助装置(LVAD)的围术期结局。匹配/校正研究中两组围术期死亡率差异无统计学意义(RR 0.86,95%CI 0.52-1.44,p=0.58),但LT与输血需求减少、因出血再手术减少及术后右心室辅助装置(RVAD)植入减少相关。

要点

  • 匹配/校正研究中LT组围术期死亡率与胸骨切开术组差异无统计学意义(RR 0.86,95%CI 0.52-1.44,p=0.58)。
  • LT与输血需求减少相关(均数差-4.7单位,95%CI -7.2至-2.3,p<0.001)。
  • LT与因出血再手术减少(RR 0.34,95%CI 0.22-0.54,p<0.001)及术后RVAD植入减少(RR 0.53,95%CI 0.36-0.77,p<0.001)相关。

核心结论

  • 经侧胸廓切开术植入LVAD与输血需求、因出血再手术及术后RVAD植入显著减少相关,这些发现支持对经过仔细选择的患者更多采用LT入路。

研究设计与样本

  • 系统评价与Meta分析,检索MEDLINE和Embase数据库,纳入25项比较经侧胸廓切开术与常规胸骨切开术植入连续流LVAD的观察性研究,共3072例患者,中位随访10个月。

主要发现

  • 围术期死亡率(30天或住院期间)LT组为7%,胸骨切开术组为14%;但在匹配/校正研究中死亡率差异不再有统计学意义(RR 0.86,95%CI 0.52-1.44,p=0.58)。
  • 匹配/校正研究中,LT与输血需求减少相关(均数差-4.7单位,95%CI -7.2至-2.3,p<0.001)。
  • 匹配/校正研究中,LT与因出血再手术减少相关(RR 0.34,95%CI 0.22-0.54,p<0.001)。
  • 匹配/校正研究中,LT与术后RVAD植入减少相关(RR 0.53,95%CI 0.36-0.77,p<0.001)。
  • 匹配/校正研究中,LT与需要正性肌力药物天数减少(均数差-1.1天,95%CI -2.1至-0.03,p=0.04)、ICU天数减少(均数差-3.3天,95%CI -6.0至-0.7,p=0.01)及住院天数减少(均数差-5.1天,95%CI -10.1至-0.1,p=0.04)相关。

关键数值与推荐

  • 匹配/校正研究中LT组与胸骨切开术组围术期死亡率差异无统计学意义(RR 0.86,95%CI 0.52-1.44,p=0.58)。
  • 匹配/校正研究中LT组输血需求低于胸骨切开术组(均数差-4.7单位,95%CI -7.2至-2.3,p<0.001)。
  • 匹配/校正研究中LT组因出血再手术风险低于胸骨切开术组(RR 0.34,95%CI 0.22-0.54,p<0.001)。
  • 匹配/校正研究中LT组术后RVAD植入风险低于胸骨切开术组(RR 0.53,95%CI 0.36-0.77,p<0.001)。
  • 匹配/校正研究中LT组需要正性肌力药物天数(均数差-1.1天,95%CI -2.1至-0.03,p=0.04)、ICU天数(均数差-3.3天,95%CI -6.0至-0.7,p=0.01)及住院天数(均数差-5.1天,95%CI -10.1至-0.1,p=0.04)均少于胸骨切开术组。

临床怎么用

  • 作者认为这些发现支持对经过仔细选择的患者更多采用经侧胸廓切开术入路植入LVAD。

局限性

  • 纳入研究均为观察性研究。
  • 匹配/校正研究中围术期死亡率差异无统计学意义(RR 0.86,95%CI 0.52-1.44,p=0.58),随访期间总死亡率在匹配/校正研究中亦无统计学显著降低(HR 0.82,95%CI 0.59-1.14,p=0.24)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Left ventricular assist device (LVAD) implantation via lateral thoracotomy can offer similar effectiveness to conventional approaches with less perioperative adverse events. We performed a systematic review and meta-analysis to determine the potential benefits of lateral thoracotomy (LT) for LVAD implantation compared to median sternotomy. METHODS: We searched MEDLINE and Embase databases for studies comparing continuous-flow LVAD implantation using LT with conventional sternotomy. Main outcomes were perioperative mortality and complications. RESULTS: Twenty-five observational studies enrolling 3072 patients were included with a median follow-up of 10 months. Perioperative mortality (30 day or in-hospital) was 7% (LT) and 14% (sternotomy); however, mortality differences were no longer statistically significant in matched/adjusted studies (RR:0.86; 95%CI:0.52-1.44; p = 0.58). LT was associated with decreased need for blood product transfusions (mean difference[MD]: -4.7; 95%CI: -7.2 to -2.3 units; p < 0.001), reoperation for bleeding (RR:0.34; 95%CI:0.22-0.54; p < 0.001), postoperative RVAD implantation (RR:0.53; 95%CI:0.36-0.77; p < 0.001), days requiring inotropes (MD: -1.1; 95%CI: -2.1 to -0.03 inotrope days; p = 0.04), ICU (MD: -3.3; 95%CI: -6.0 to -0.7 ICU days; p = 0.01), and hospital length of stay (MD: -5.1; 95%CI: -10.1 to -0.1 hospital days; p = 0.04) in matched/adjusted studies. Overall mortality during follow-up was significantly lower for LT in unmatched/unadjusted studies but not statistically significantly lower in matched/adjusted studies (Hazard Ratio:0.82; 95%CI:0.59-1.14; p = 0.24). CONCLUSION: LVAD implantation via LT was associated with significantly decreased need for blood products, reoperation for bleeding, and postoperative RVAD implantation. Furthermore, days on inotropic support were also lower, likely contributing to the shorter length of stay. These findings support greater use of a LT approach for carefully selected patients.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Ribeiro RVP, Lee J, Elbatarny M, et al. Left ventricular assist device implantation via lateral thoracotomy: A systematic review and meta-analysis. J Heart Lung Transplant. 2022. PMID: 35953353. doi:10.1016/j.healun.2022.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。